Curated News: Medical Meetings

Filters close
1-May-2023 3:20 PM EDT
Clinical Outcomes of more than 500 Lung Transplants using Ex vivo Lung Perfusion: A Large-Volume, Single-Center Retrospective Analysis
American Association for Thoracic Surgery (AATS)

To compare the outcomes of patients receiving lungs transplanted after undergoing ex vivo lung perfusion (EVLP) versus those transplanted conventionally at the Toronto General Hospital, Aadil Ali, PhD, and coauthors looked at 14 years of data from the Toronto Lung Transplant Database.

1-May-2023 4:10 PM EDT
Long-term Outcome of Patients with Peripheral Ground Glass Opacity Dominant Lung Cancer After Sublobar Resections
American Association for Thoracic Surgery (AATS)

In 2011, Makoto Suzuki, MD, and a team of associates from across Japan embarked on a long-term study of the safety and efficacy of sublobar resections for ground-glass opacity–dominant (GGO) peripheral lung cancer.

Newswise: Prognostic Utility of a Novel Risk Prediction Model for 1-Year Mortality Following Surgery for Congenital or Acquired Heart Disease
1-May-2023 4:25 PM EDT
Prognostic Utility of a Novel Risk Prediction Model for 1-Year Mortality Following Surgery for Congenital or Acquired Heart Disease
American Association for Thoracic Surgery (AATS)

Congenital heart disease (CHD) is the most common type of birth defect and the leading cause of mortality from birth defects, affecting about 1% of all live births per year in the United States. With advances in medical therapies and surgical techniques, the survival outcomes of patients with CHD have improved dramatically over the years.

1-May-2023 3:35 PM EDT
Results of Early Monitoring of Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer
American Association for Thoracic Surgery (AATS)

Among the questions that cancer patients ask following their surgeries are, “Will it come back? Do I need additional treatment?”

1-May-2023 3:55 PM EDT
Apixaban vs. Warfarin in Patients with an On-X Mechanical Aortic Valve
American Association for Thoracic Surgery (AATS)

Although the On-X aortic valve and apixaban have been approved for use by the U.S. Food and Drug Administration (FDA), they had not been approved to be used together. Between May 2020 and September 2022, the PROACT Xa randomized, multicenter, open-label trial compared the direct factor Xa inhibitor apixaban (Eliquis) with warfarin in patients with bileaflet carbon aortic valves.

1-May-2023 4:30 PM EDT
Safety and Efficacy of Delaying Nighttime Lung Transplantation
American Association for Thoracic Surgery (AATS)

Lung transplantation is routinely performed at night because of the unpredictability of donor organ procurement. Late start-times for complex operations such as lung transplantation have been associated with adverse outcomes.



close
3.00394